Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1 | Zendy

Melissa Cudmore | Zendy; Shakil Ahmad | Zendy; Bahjat AlAni | Zendy; Takeshi Fujisawa | Zendy; Heather Coxall | Zendy; Kunal Chudasama | Zendy; Luke Devey | Zendy; Stephen J. Wigmore | Zendy; Allyah Abbas | Zendy; Peter W. Hewett | Zendy; Asif Ahmed | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1

Author(s) -

Melissa Cudmore,

Shakil Ahmad,

Bahjat AlAni,

Takeshi Fujisawa,

Heather Coxall,

Kunal Chudasama,

Luke Devey,

Stephen J. Wigmore,

Allyah Abbas,

Peter W. Hewett,

Asif Ahmed

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.660134

Subject(s) - preeclampsia , heme oxygenase , medicine , downregulation and upregulation , placental growth factor , endoglin , endocrinology , vascular endothelial growth factor , endothelial dysfunction , heme , pharmacology , chemistry , biology , vegf receptors , microbiology and biotechnology , biochemistry , pregnancy , genetics , stem cell , gene , cd34 , enzyme

Preeclampsia is characterized clinically by hypertension and proteinuria. Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1]) and soluble endoglin (sEng) are elevated in preeclampsia, and their administration to pregnant rats elicits preeclampsia-like symptoms. Heme oxygenase-1 (HO-1) and its metabolite carbon monoxide (CO) exert protective effects against oxidative stimuli. Thus, we hypothesized that HO-1 upregulation may offer protection against preeclampsia by inhibiting sFlt-1 and sEng release.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research